A Phase 2 Open-Label Study Of Danicopan (Ach-0144471) In Patients With Paroxysmal Nocturnal Hemoglobinuria (Pnh) Who Have An Inadequate Response To Eculizumab Monotherapy
BLOOD(2019)
Abstract
Background: PNH is a rare, acquired blood disorder. A somatic mutation in the PIGA gene of one or more hematopoietic stem cells generates a clone of abnormal erythrocytes (RBCs) that lack alternative pathway (AP) regulatory complement proteins CD55 and CD59. This leads to uncontrolled complement activation on affected RBCs and intravascular hemolysis (IVH).
MoreTranslated text
Key words
paroxysmal nocturnal hemoglobinuria,danicopan,open-label
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined